(News Bulletin 247) – Sanofi announced on Monday that Canada has authorized the use of its respiratory syncytial virus (RSV) vaccine developed with AstraZeneca.
The French laboratory indicates that Health Canada has issued a notice of compliance approving Beyfortus for the prevention of lower respiratory tract infections caused by RSV.
Its green light is for administration to newborns and infants during the first circulating season of the virus they face.
The authorization also applies to children under the age of 24 months who remain susceptible to RSV infections during the second RSV circulation season they face.
Highly contagious, RSV is a common seasonal respiratory virus that infects almost all children before the age of two and can cause serious illnesses, including bronchiolitis and pneumonia.
It is now one of the leading causes of hospitalization of infants in Canada.
Sanofi says it plans to bring Beyfortus to market by the next 2023-2024 VRS circulation season.
Copyright (c) 2023 News Bulletin 247. All rights reserved.
I have over 8 years of experience working in the news industry. I have worked as a reporter, editor, and now managing editor at 247 News Agency. I am responsible for the day-to-day operations of the news website and overseeing all of the content that is published. I also write a column for the website, covering mostly market news.
